ZELTIQ Aesthetics Inc. 02.01.17
ZELTIQ Aesthetics Inc., a developer and commercializer of products using its proprietary controlled-cooling technology, has announced that CoolSculpting is U.S. Food and Drug Administration (FDA)-cleared for upper arms, making it the only non-invasive fat removal technology cleared by the agency to address this body area.
“There are 29 million people in the U.S. interested in CoolSculpting, with more than 14 million expressing concern about unwanted arm fat, making arms the third most popular area for consideration of non-invasive fat reduction,” said Mark Foley, president and CEO of ZELTIQ. "As demonstrated with our recent FDA clearance, we are committed to investing in R&D and clinical research to provide consumers with solutions that they desire most. CoolSculpting’s ability to successfully treat upper arm fat is a testament to our technology’s efficacy and versatility, as well as our position as the leader in non-invasive fat reduction.”
The company also announced that it will be launching the CoolAdvantage Petite applicator for the CoolSculpting system to optimize the performance of CoolSculpting in the upper arms, with full commercial release targeted for the middle part of the year. The newest member of the CoolAdvantage family of applicators, the CoolAdvantage Petite treatment comes with two interchangeable contours designed to uniquely treat the upper arm area in just 35 minutes.
"My patients have been asking for a non-invasive solution for their unwanted arm fat so I am thrilled to be able to offer them a proven solution that is safe and effective," said Grant Stevens, M.D., FACS, founder and medical director of Marina Plastic Surgery and medical director of Body by OrangeTwist. "We anticipate a lot of interest from our patients now that there is an FDA-cleared solution to treat this challenging area."
CoolSculpting is a safe and effective treatment for non-invasive fat reduction with unmatched clinical evidence. With more than 70 peer-reviewed clinical papers and abstracts and more than 3.5 million treatments performed to date in over 80 countries around the world, CoolSculpting is the leader in non-invasive fat reduction. CoolSculpting is FDA-cleared for the treatment of fat bulges in the submental area, thigh, abdomen, flank, bra and back fat area, underneath the buttocks and now, the upper arm.
CoolSculpting is available through an elite network of CoolSculpting Centers worldwide.
CoolSculpting is a non-surgical, clinically proven procedure that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed by more than 5,700 CoolSculpting systems. Market research indicates up to a 95 percent customer satisfaction rate with the CoolSculpting procedure.
ZELTIQ’s first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
“There are 29 million people in the U.S. interested in CoolSculpting, with more than 14 million expressing concern about unwanted arm fat, making arms the third most popular area for consideration of non-invasive fat reduction,” said Mark Foley, president and CEO of ZELTIQ. "As demonstrated with our recent FDA clearance, we are committed to investing in R&D and clinical research to provide consumers with solutions that they desire most. CoolSculpting’s ability to successfully treat upper arm fat is a testament to our technology’s efficacy and versatility, as well as our position as the leader in non-invasive fat reduction.”
The company also announced that it will be launching the CoolAdvantage Petite applicator for the CoolSculpting system to optimize the performance of CoolSculpting in the upper arms, with full commercial release targeted for the middle part of the year. The newest member of the CoolAdvantage family of applicators, the CoolAdvantage Petite treatment comes with two interchangeable contours designed to uniquely treat the upper arm area in just 35 minutes.
"My patients have been asking for a non-invasive solution for their unwanted arm fat so I am thrilled to be able to offer them a proven solution that is safe and effective," said Grant Stevens, M.D., FACS, founder and medical director of Marina Plastic Surgery and medical director of Body by OrangeTwist. "We anticipate a lot of interest from our patients now that there is an FDA-cleared solution to treat this challenging area."
CoolSculpting is a safe and effective treatment for non-invasive fat reduction with unmatched clinical evidence. With more than 70 peer-reviewed clinical papers and abstracts and more than 3.5 million treatments performed to date in over 80 countries around the world, CoolSculpting is the leader in non-invasive fat reduction. CoolSculpting is FDA-cleared for the treatment of fat bulges in the submental area, thigh, abdomen, flank, bra and back fat area, underneath the buttocks and now, the upper arm.
CoolSculpting is available through an elite network of CoolSculpting Centers worldwide.
CoolSculpting is a non-surgical, clinically proven procedure that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed by more than 5,700 CoolSculpting systems. Market research indicates up to a 95 percent customer satisfaction rate with the CoolSculpting procedure.
ZELTIQ’s first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.